序贯化疗系统性免疫球蛋白轻链型淀粉样变性肾病1例

doi:10.3969/j.issn.1004-583X.2021.03.016

临床荟萃 ›› 2021, Vol. 36 ›› Issue (3): 266-269.doi: 10.3969/j.issn.1004-583X.2021.03.016

序贯化疗系统性免疫球蛋白轻链型淀粉样变性肾病1例

高兴连, 童宗武(), 杨崇猛, 赵艳红, 卢永新, 丁蓉

昆明医科大学第六附属医院肾内科,云南玉溪 653100

收稿日期:2020-09-28 出版日期:2021-03-20 发布日期:2021-03-29
通讯作者: 童宗武 E-mail:tongzongwud@126.com
基金资助:
云南省卫生健康委员会医学后备人才培养计划——肾脏病学方向(H-2018053)

A case of AL type amyloidosis nephropathy treated with sequential chemotherapy

Gao Xinglian, Tong Zongwu(), Yang Chongmeng, Zhao Yanhong, Lu Yongxin, Ding Rong

Department of Nephrology, the Sixth Affiliated Hospital of Kunming Medical University, Yuxi 653100, China

Received:2020-09-28 Online:2021-03-20 Published:2021-03-29
Contact: Tong Zongwu E-mail:tongzongwud@126.com

摘要/Abstract

摘要：

阐述1例AL型淀粉样变性肾病的男性患者,以浮肿、少尿、腹胀、低蛋白血症、高脂血症、大量蛋白尿为主要临床表现,经肾脏穿刺病理活检确诊。经过序贯使用“CBD”、“TCD”化疗方案治疗,患者病情好转,现取得很好的部分缓解的疗效。本文就AL型淀粉样变性肾病的诊治、预后评估等方面进行探讨。

关键词: 肾疾病, 淀粉样变性, 药物疗法, 联合

Abstract:

A male patient with AL type amyloidosis nephropathy was presented. The main clinical manifestations were edema, oliguria, abdominal distension, hypoproteinemia, hyperlipidemia and massive proteinuria. The diagnosis was confirmed by renal biopsy. After the sequential use of “CBD” and “TCD” chemotherapy, the patient's condition improved and good partial remission was achieved. The diagnosis, treatment and prognosis of AL type amyloidosis nephropathy were discussed in the article.

Key words: kidney disease, amyloidosis, drug therapy, combination

中图分类号:

R692

高兴连, 童宗武, 杨崇猛, 赵艳红, 卢永新, 丁蓉. 序贯化疗系统性免疫球蛋白轻链型淀粉样变性肾病1例[J]. 临床荟萃, 2021, 36(3): 266-269.

Gao Xinglian, Tong Zongwu, Yang Chongmeng, Zhao Yanhong, Lu Yongxin, Ding Rong. A case of AL type amyloidosis nephropathy treated with sequential chemotherapy[J]. Clinical Focus, 2021, 36(3): 266-269.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.03.016

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I3/266

图/表 4

参考文献 15

[1]	焦晨峰, 姜玲, 赵丽丽, 等. 芬兰型肾淀粉样变性合并膜性肾病一例[J]. 中华肾脏病杂志, 2020,36(4):312-314.
[2]	Huang XH, Liu ZH. The clinical presentation and management of systemic light-chain amyloidosis in China[J]. Kidney Dis (Basel), 2016,2(1):1-9.
[3]	Prakash J, Brojen T, Rathore SS, et al. The changing pattern of renal amyloidosis in Indian subcontinent: Two decades of experience from a single center[J]. Ren Fail, 2012,34(10):1212-1216. doi: 10.3109/0886022X.2012.723514 pmid: 23009273
[4]	毕春丽, 张磊, 金晓明. 淀粉样变肾病研究进展[J]. 国际免疫学杂志, 2017,40(1):65-69.
[5]	Leung N. To biopsy or not to biopsy, that is the question in myeloma cast nephropathy[J]. Nephrol Dial Transplant, 2016,31:1-3. doi: 10.1093/ndt/gfv294 URL
[6]	李思倩, 朱子璇, 文煜冰, 等. 多发性骨髓瘤管型肾病和肾淀粉样变性的临床特征及预后分析[J]. 基础医学与临床, 2019,39(10):1483-1487.
[7]	中国系统性淀粉样变性协作组, 国家肾脏疾病临床医学研究中心. 系统性轻链型淀粉样变性诊断和治疗指南[J]. 中华医学杂志, 2016,96(44):3540-3548.
[8]	黄湘华. 硼替佐米治疗轻链型淀粉样变性的经验浅谈[J]. 肾脏病与透析肾移植杂志, 2017,26(3):255-256.
[9]	Milani P, Sharpley F, Schönland SO, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: A European retrospective series of 153 patients[J]. Amyloid, 2020,27(4):231-236. doi: 10.1080/13506129.2020.1767566 URL
[10]	Zumbo G, Sadeghi-Alavijeh O, Hawkins PN, et al. New and developing therapies for AL amyloidosis[J]. Expert Opin Pharmaco, 2016,18(2):139-149. doi: 10.1080/14656566.2016.1274971 URL
[11]	Sanchorawala V, Sun F, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience[J]. Blood, 2015,126(20):2345-2347. doi: 10.1182/blood-2015-08-662726 pmid: 26443620
[12]	林泽宇, 陈文明. 轻链型淀粉样变性的诊断及治疗进展[J]. 白血病·淋巴瘤, 2019,28(1):57-60.
[13]	Nuvolone M, Merlini G. Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis[J]. Expert Opin Ther Targets, 2017,21(12):1095-1110. doi: 10.1080/14728222.2017.1398235 URL
[14]	Blank N, Hegenbart U, Schönland S. Causes and treatment of systemic amyloidosis[J]. Z Rheumatol, 2016,75(2):141-150. doi: 10.1007/s00393-015-0024-8 pmid: 88583477603209274
[15]	Angel-Korman A, Jaberi A, Sanchorawala V, et al. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis[J]. Amyloid, 2020,27(1):17-24. doi: 10.1080/13506129.2019.1672650 pmid: 31595786

序贯化疗系统性免疫球蛋白轻链型淀粉样变性肾病1例

A case of AL type amyloidosis nephropathy treated with sequential chemotherapy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 15

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王超, 万多, 李卅立, 王曦. 颈动脉多普勒超声对慢性肾病患者动脉粥样硬化程度及血流动力学的评估价值[J]. 临床荟萃, 2021, 36(11): 1009-1012.
[2]	狄佳1a，周华1a，李旻1a，徐婷1b，赵家璧2. 肾小管上皮细胞来源包含miroRNA-21的微囊泡在心肌肥大中的作用[J]. 临床荟萃, 2020, 35(3): 245-250.
[3]	刘晨菲，耿丽娟，郑新伟，张赛，刘惠苗，顾平. 慢性肾脏病伴不安腿综合征的研究进展[J]. 临床荟萃, 2020, 35(3): 277-281.
[4]	于澈, 赵雪, 王荣. 基于新冠肺炎中ACE2的作用及其在肾脏疾病发病机制中的新认识[J]. 临床荟萃, 2020, 35(11): 1053-1056.
[5]	吴鹏，张佳晨，沈蕾. 慢性肾脏病患者血压形态特点及临床疗效分析[J]. 临床荟萃, 2020, 35(10): 914-921.
[6]	董晶倩，高山林. 成纤维细胞生长因子23、Klotho及相关信号转导通路在继发性甲状旁腺功能亢进中的研究进展[J]. 临床荟萃, 2019, 34(4): 373-376.
[7]	邹丹丹, 张海松, 汪煜. 成纤维细胞生长因子23信号通路在慢性肾脏病及相关并发症中的作用[J]. 临床荟萃, 2019, 34(12): 1143-1147.
[8]	康英丽，李英. 2018年肾脏疾病研究进展[J]. 临床荟萃, 2019, 34(1): 56-63.
[9]	徐瑶瑶，王保兴. 头静脉弓狭窄的研究进展[J]. 临床荟萃, 2018, 33(7): 629-632.
[10]	王娜，李培兰. 急诊重症监护室急性肾功能损伤患者的临床特征及预后分析[J]. 临床荟萃, 2018, 33(4): 319-322,328.
[11]	于红燕a，杨海平b，耿文彦a，张瑞凤a，李瑞英a，葛世杰a. 慢性肾脏病患者左心室舒张期功能障碍的影响因素分析[J]. 临床荟萃, 2018, 33(11): 974-977,982.
[12]	刘传芬，陈红. 心脏淀粉样变诊治进展[J]. 临床荟萃, 2018, 33(11): 999-1001.
[13]	王泽凯，胡志娟，董春霞，牛凯，刘冰. 血浆ghrelin与慢性肾脏病并发症[J]. 临床荟萃, 2018, 33(10): 849-853.
[14]	高少辉，徐金升. LncRNA GAS5与肾脏病发生关系[J]. 临床荟萃, 2018, 33(10): 846-848.
[15]	王江丽，张文贤，赵嘉懿，刘茂东，李英. 肠道微生态与慢性肾脏病[J]. 临床荟萃, 2017, 32(6): 537-540,544.